MedTrace Logo

CAcTUS - Circulating Tumour DNA Guided Switch

NCT03808441 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2023-08-25

No results posted yet for this study

Summary

The stay aims to determine whether switching from targeted therapy to immunotherapy based on a decrease in levels of circulating tumour DNA in the blood, will improve the outcome in melanoma patients.

Conditions

Interventions

OTHER

ctDNA analysis

Regular ctDNA analysis, which upon a decrease in mutant BRAF VAF (variant allele frequency) level of ≥80% the switch to N+I is triggered.

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • University of Manchester

    collaborator OTHER

  • Manchester Academic Health Science Centre

    collaborator OTHER

  • The Christie NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Paul Lorigan · The Christie National Health Service (NHS) Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-02
Primary Completion
2023-04-26
Completion
2024-05-02

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03808441 on ClinicalTrials.gov